Al Jalila Foundation, a member of the Mohammed Bin Rashid Al Maktoum Global Initiatives, has announced that it will introduce the UAE’s first robotic bank in partnership with the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) and the Dubai Health Authority (DHA).
The biobank, which is set to open in 2023, will be located at the Mohammed Bin Rashid Medical Research Institute, part of Al Jalila Foundation, in Dubai Healthcare City. This partnership will focus on areas around genetic disorders, cancer and other chronic diseases and pandemics.
Sheikh Ahmed bin Saeed Al Maktoum, Chairperson of Al Jalila Foundation Board of Trustees, said, “Access to genetic and imaging data through biobanks is driving forward pioneering approaches to analysis that would have been impossible just a few years ago. The launch of the UAE’s first robotic biobank reflects Dubai’s commitment to strengthening the capabilities of the healthcare sector and advancing efforts to improve people’s health. The biobank will serve as a major contributor to the advancement of modern medicine and will enable scientific discoveries that will help enhance the health and wellbeing of the community.”
Due to the vital role biobanks play in progressing research and advancing medical discovery, the biobank will become an indispensable resource for the new Hamdan Bin Rashid Cancer Charity Hospital and other healthcare facilities in the UAE to conduct research and offer effective treatment, says Gulf News.
Dr Raja Easa Al Gurg, the chairperson of Al Jalila Foundation Board of Directors and Member of the Board of Trustees, said, “Biobanking is a game-changer for health care and will revolutionise medical research, leading to better outcomes for patient treatment. The biobank will provide an opportunity for people in the community and researchers to work together to build a better, healthier future for generations to come. Scientific progress will shape the nation’s economy by influencing our knowledge about human health, disease, therapeutics, personalised medicine, and more.”